March 24, 2020 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for Eucrisa® (crisaborole) ointment, 2%, extending the lower age limit from 24…Original Article
FDA Approves Eucrisa (crisaborole) Ointment 2% in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis
